Medication info

Idian Duo Tablet 5/500 mg

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›5mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Il Yang Pharmaceutical Co., Ltd.
Appearance
Orange-yellow, oval, film-coated tablet with convex surfaces
Packaging
10 tablets/box (10 tablets/PTP x 1), 60 tablets/box (10 tablets/PTP x 6), 60 tablets/bottle
Approval status
Active

MFDS item code 202201337 · Approved 2022.04.04

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes
Who takes it
Adults
Adult dose
The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other medicines such as insulin, the recommended dose is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient's current metformin dose. If empagliflozin 10 mg (total daily dose) is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching to this medicine from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin should receive their previous doses of empagliflozin and metformin. When this medicine is used concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you miss a dose, take it as soon as you remember. However, do not take twice the dose at one time; in this case, skip the missed dose. Special Populations Patients with Renal Impairment No dose adjustment is required for patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who have no other condition that may increase the risk of lactic acidosis. In these patients, the starting dose of metformin is 500 mg or 850 mg once daily, so treatment should be initiated with the individual single-ingredient products empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, which may be given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see Precautions for Use, 3. Patients Requiring Caution, item 1)). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, discontinue this medicine immediately (see Precautions for Use, 2. Do not administer to the following patients, item 2)). Elderly Patients In patients aged 75 years or older, consider renal function and the risk of volume depletion.

Ingredients

Manufacturer
Il Yang Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes

View approved original text

This medication is used to assist adults with Type 2 diabetes in controlling blood sugar levels in conjunction with dietary and exercise therapy. In particular, it helps manage blood sugar levels effectively by administering empagliflozin and metformin together. It can also be administered to adults with Type 2 diabetes who are not adequately controlled and have cardiovascular disease; caution related to cardiovascular event occurrence should refer to professional information. This medication improves blood sugar management and aids in the treatment of Type 2 diabetes.

How to take

Adult dose

The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other medicines such as insulin, the recommended dose is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient's current metformin dose. If empagliflozin 10 mg (total daily dose) is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching to this medicine from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin should receive their previous doses of empagliflozin and metformin. When this medicine is used concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you miss a dose, take it as soon as you remember. However, do not take twice the dose at one time; in this case, skip the missed dose. Special Populations Patients with Renal Impairment No dose adjustment is required for patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who have no other condition that may increase the risk of lactic acidosis. In these patients, the starting dose of metformin is 500 mg or 850 mg once daily, so treatment should be initiated with the individual single-ingredient products empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, which may be given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see Precautions for Use, 3. Patients Requiring Caution, item 1)). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, discontinue this medicine immediately (see Precautions for Use, 2. Do not administer to the following patients, item 2)). Elderly Patients In patients aged 75 years or older, consider renal function and the risk of volume depletion.

Precautions

This medication can cause a rare but very serious condition called lactic acidosis, so you must consult a doctor immediately if any symptoms appear. In addition, there is a risk of hypoglycemia when used together with insulin or sulfonylureas, so caution is needed. This medication should not be used in patients with moderate to severe kidney impairment, acute kidney problems, severe infections, or dehydration. Patients with Type 1 diabetes or those in acute or unstable heart failure should also avoid this medication. Before and after diagnostic tests using radioactive iodine contrast agents, this medication should be temporarily discontinued, and it should be resumed after kidney function has returned to normal. Pregnant or breastfeeding women should not take this medication, and if there is a possibility of pregnancy, they should consult a doctor. Regular kidney function tests should be performed during the use of this medication, especially for the elderly or those with slightly impaired kidney function, as more frequent testing is advisable. In cases with a risk of fluid loss, such as vomiting, diarrhea, or dehydration symptoms, the use of this medication may be temporarily suspended. This medication may cause side effects such as gastrointestinal disturbances, urinary tract infections, genital infections, and increased urination, so report any unusual symptoms to a doctor. Long-term use may lower vitamin B12 levels, so blood tests to check vitamin B12 status are necessary. Alcohol can increase the risk of side effects of this medication, so excessive drinking should be avoided during use. Hypoglycemic symptoms may occur while taking this medication, especially when used along with insulin or other hypoglycemic agents, so blood sugar should be monitored carefully. If food intake is restricted due to surgery or serious illness, this medication should be stopped 48 hours before surgery and resumed after kidney function has returned to normal. This medication is not recommended for children or adolescents under the age of 18, and dosage adjustments are necessary for the elderly based on kidney function. In case of overdose, seek medical attention immediately for appropriate treatment, as serious side effects such as lactic acidosis may occur. Keep this medication out of the reach of children and store it in its original container to maintain its quality.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • decreased and deficiency of Vitamin B12
  • ketoacidosis
  • lactic acidosis
  • decreased fluid volume
Show 193 more
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • constipation
  • abnormal liver function tests
  • hepatitis
  • dysgeusia
  • itching
  • rash
  • urticaria
  • erythema multiforme
  • difficulty urinating
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • vulvovaginitis
  • balanitis
  • perineal necrosis
  • decreased blood sugar
  • hypotension
  • dehydration
  • low blood pressure
  • decreased blood volume
  • orthostatic hypotension
  • syncope
  • abnormal liver function
  • chronic gastritis
  • cerebral infarction
  • soft tissue infection
  • pneumonia
  • ankle fracture
  • epicondylitis
  • facial bone fracture
  • musculoskeletal pain
  • myocardial infarction
  • pancreatic carcinoma
  • urosepsis
  • pyelonephritis
  • rash
  • urticaria
  • angioedema
  • perineal necrosis
  • constipation
  • gastritis
  • gastrointestinal disorders
  • oral discomfort
  • salivary gland pain
  • headache
  • sensory disturbance
  • positional dizziness
  • dizziness
  • weakness
  • chest discomfort
  • chest pain
  • nasopharyngitis
  • upper respiratory tract infection
  • bronchitis
  • chronic sinusitis
  • gastroenteritis
  • Helicobacter infection
  • periodontitis
  • appendiceal abscess
  • appendicitis
  • chronic tonsillitis
  • conjunctivitis
  • influenza
  • laryngitis
  • meningitis
  • chronic otitis media
  • paronychia
  • peritonsillar abscess
  • pulmonary tuberculosis
  • sepsis
  • subcutaneous abscess
  • tinea corporis
  • dental abscess
  • adnexal abscess
  • vestibular neuritis
  • drowsiness
  • CNS-origin vertigo
  • fatigue
  • peripheral edema
  • facial edema
  • peripheral swelling
  • fever
  • facial swelling
  • chills
  • strange feeling
  • edema
  • pain
  • pain at the puncture site
  • vascular stent stenosis
  • vascular stent thrombosis
  • weight loss
  • vulvar pruritus
  • benign prostatic hyperplasia
  • diabetic retinopathy
  • diplopia
  • epistaxis
  • asthma
  • exertional dyspnea
  • wet cough
  • allergic rhinitis
  • residual sputum
  • skin abrasion
  • contusion
  • rib fracture
  • concussion
  • corneal abrasion
  • fall
  • hand fracture
  • ligamentum flavum syndrome
  • open globe injury
  • pelvic fracture
  • road traffic accident
  • splenic injury
  • sternum fracture
  • palpitations
  • tachycardia
  • arteriosclerosis
  • deep vein thrombosis
  • diabetic vascular complications
  • peripheral arterial occlusive disease
  • anxiety
  • depression
  • sleep disorders
  • acute cholecystitis
  • autoimmune hepatitis
  • cholelithiasis
  • hepatitis
  • otalgia
  • positional vertigo
  • vertigo
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid nodule
  • diarrhea
  • nausea
  • gastric ulcer
  • colitis
  • vomiting
  • ischemic colitis
  • colonic hemorrhage
  • cerebral infarction
  • headache
  • sensory disturbance
  • positional dizziness
  • dizziness
  • cerebral infarction
  • headache
  • positional dizziness
  • fever
  • vascular stent stenosis
  • vascular stent thrombosis
  • ankle fracture
  • epicondylitis
  • facial bone fracture
  • ligament injury
  • ligament sprain
  • arthralgia
  • lumbago
  • musculoskeletal pain
  • osteopenia
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurriness
  • corneal erosion
  • glaucoma
  • macular fibrosis
  • ocular discomfort
  • conjunctival injection
  • pathological myopia
  • retinal detachment
  • retinal deposits
  • retinal vein occlusion
  • retinal detachment with holes
  • eyelid swelling
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • epistaxis
  • asthma
  • allergic rhinitis
  • cough
  • unstable angina
  • hypertension
  • insomnia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly closed container to prevent exposure to air or moisture. It is essential to maintain a storage temperature between 1°C and 30°C at room temperature. Proper storage can help maintain the effectiveness of the medication for a longer period.

Appearance and packaging

Appearance

Orange-yellow, oval, film-coated tablet with convex surfaces

Package unit

10 tablets/box (10 tablets/PTP x 1), 60 tablets/box (10 tablets/PTP x 6), 60 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.